Rhapsido (Remibrutinib) 25mg is an innovative oral BTK inhibitor designed to treat adults with chronic spontaneous urticaria (CSU) unresponsive to antihistamines. By selectively blocking Bruton’s tyrosine kinase, it prevents the activation of mast cells, reducing histamine release and alleviating itching, swelling, and wheals. Developed by Novartis, Rhapsido offers a targeted, once-daily solution for persistent urticaria symptoms, helping patients regain comfort and quality of life.
$5,995.00
| Active Ingredient | Remibrutinib |
|---|---|
| Indication | Indicated for adult patients with chronic spontaneous urticaria (CSU) who do not achieve symptom control with H1-antihistamines. |
| Origin | United States of America |
| Packaging | 25mg |
| Storage Temperature | Controlled room temperature |
| Strength | 60 tablets |